AR006518A1 - Esteres de derivados de 1,4-piperidina disustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y un procedimiento para su preparacion - Google Patents

Esteres de derivados de 1,4-piperidina disustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y un procedimiento para su preparacion

Info

Publication number
AR006518A1
AR006518A1 ARP970100789A ARP970100789A AR006518A1 AR 006518 A1 AR006518 A1 AR 006518A1 AR P970100789 A ARP970100789 A AR P970100789A AR P970100789 A ARP970100789 A AR P970100789A AR 006518 A1 AR006518 A1 AR 006518A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
alk
cycloalkyl
procedure
Prior art date
Application number
ARP970100789A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR006518A1 publication Critical patent/AR006518A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invenciión se refiere a nuevos esteres de derivados de 1,4- piperidina disubstituida de fórmula I; las formas N-óxido, las sales de adiciónde ácidos farmacéuticamente aceptables de la misma, o las formas estereoquímicam enteisoméricas de la misma caracterizado porque R1 es alquiloxiC1-6, alqueniloxi C2-6 o alquiniloxi C2-6; R2 es hidrógeno o alquiloxi C1-6 o cuando R1 y R2 en conjunto pueden formar un radical bivalente de fórmula,cuando en dichos radicales bivalentes uno o dos átomos de hidrógeno pueden ser sustituídos con alquilo C1-6; R3 es hidrógeno o halo; L es cicloalquilo C3-6cicloalcanona C5-6 alquenilo CC2-6 sustituido opcionalmente con Ar o L es un radical de fórmula -Alk-R4, -Alk-NR5R6, 1-R64-p iperidinilo, Alk-X-R7, -Alk-Y-C--(=O)-R9, o Alk-Y-C(=O=-NR11R12, donde cada Alk es alcanodilo X1-12; R4 es hidrógeno o alquilsulfonilamino C1-6, cicloalquilo C3-6, cicloalcanona C5-6 di(Ar) metilo, Ar-oxi- o Het 1; R5 es hidrógeno, alquilo C1- 6; R6 es Het2, R7 es hidrógeno, alquilo C1-6, hidroxi alquilo C1-6, cicloalquilo C3-6, Ar o Het2, Xes O,S,SO2 o NR8, siendo R8 hidrógeno, alquilo C1-6 o AR; R9 es hidrógeno, alquilo C1-6, cicloalquilo C3-6, Ar, Ar alquilo C1-6, di (Ar)metilo, a lquiloxiC1-6 o hidroxi; Y es NR10 o un enlace directo; siendo dicho R10 hidrógeno, alquilo C1-6 o Ar; R11 y R12 son cada uno en forma independiente, hidrógeno,alquilo C1-6, cicloalquilo C3-6, Ar o Ar alquilo C1-6 o R11 y R12 en formacombin ada con R11 y R12 con carga de átomo de nitrógeno que pueden formar unanillo de pirrolidinilo o piperidinilo, ambos siendo opcionalment sustituidos con alquilo C1-6 amino o mono o di (alquilo C1-6) amino, o dichos R11 y R12combinado con R11y R12 c on carga de nitrógeno de R11 y R12 pueden formar un radical de piperazinilo o de 4-morfolinilo, ambos siendo opcionalmente
ARP970100789A 1996-02-29 1997-02-27 Esteres de derivados de 1,4-piperidina disustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y un procedimiento para su preparacion AR006518A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96200525 1996-02-29

Publications (1)

Publication Number Publication Date
AR006518A1 true AR006518A1 (es) 1999-09-08

Family

ID=8223729

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970100789A AR006518A1 (es) 1996-02-29 1997-02-27 Esteres de derivados de 1,4-piperidina disustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y un procedimiento para su preparacion

Country Status (14)

Country Link
US (3) US6291481B1 (es)
EP (1) EP0885190B1 (es)
JP (1) JP2000505461A (es)
KR (1) KR100485148B1 (es)
AR (1) AR006518A1 (es)
AT (1) ATE239706T1 (es)
AU (1) AU724401B2 (es)
DE (1) DE69721742T2 (es)
ES (1) ES2199341T3 (es)
ID (1) ID17758A (es)
MY (1) MY121632A (es)
TW (1) TW445263B (es)
WO (1) WO1997031897A1 (es)
ZA (1) ZA971735B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW445263B (en) * 1996-02-29 2001-07-11 Janssen Pharmaceutica Nv Novel esters of 1,4-disubstituted piperidine derivatives
TW570920B (en) * 1998-12-22 2004-01-11 Janssen Pharmaceutica Nv 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders
GB0002312D0 (en) * 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
US7065096B2 (en) * 2000-06-23 2006-06-20 Mips Technologies, Inc. Method for allocating memory space for limited packet head and/or tail growth
ATE295845T1 (de) * 2002-01-16 2005-06-15 Janssen Pharmaceutica Nv Prucaloprid-n-oxid
US7550590B2 (en) * 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
DE602004022819D1 (de) * 2003-06-06 2009-10-08 Vertex Pharma Von atp-bindende kassette transportern
CA2546300C (en) 2003-11-20 2012-10-02 Janssen Pharmaceutica N.V. 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
CA2546002C (en) 2003-11-20 2012-09-18 Janssen Pharmaceutica N.V. 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
WO2005092882A1 (en) * 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
ES2563954T3 (es) 2004-06-30 2016-03-16 Janssen Pharmaceutica Nv Derivados de ftalazina como inhibidores de PARP
CN1980913B (zh) 2004-06-30 2011-12-14 詹森药业有限公司 作为parp抑制剂的喹唑啉二酮衍生物
MXPA06014543A (es) 2004-06-30 2007-03-23 Janssen Pharmaceutica Nv Derivados de quinazolinona como inhibidores de la poli(adp-ribosa)polimerasa-i.
WO2008107478A1 (en) 2007-03-08 2008-09-12 Janssen Pharmaceutica Nv Quinolinone derivatives as parp and tank inhibitors
JP5525447B2 (ja) 2007-10-26 2014-06-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐ阻害剤としてのキノリノン誘導体
WO2009118382A1 (en) 2008-03-27 2009-10-01 Janssen Pharmaceutica Nv Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors
JP5464609B2 (ja) 2008-03-27 2014-04-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チューブリン重合阻害剤としてのキナゾリノン誘導体
CN107848984B (zh) * 2015-03-13 2021-08-24 米洛诺瓦创新有限责任公司 用于制备麦角硫因化合物的Nα,Nα,Nα-三烷基组氨酸衍生物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2116024A1 (en) 1991-08-20 1993-03-04 Francis David King 5-ht4 receptor antagonists
EP0604494B1 (en) 1991-09-12 1999-07-28 Smithkline Beecham Plc 5-ht4 receptor antagonists
JPH07503480A (ja) 1992-02-06 1995-04-13 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５−ｈｔ４拮抗薬としてのベンゾピラン，ベンゾチオピランおよびベンゾフラン誘導体
US5708174A (en) 1992-03-12 1998-01-13 Smithkline Beecham P.L.C. Heterocyclic-esters or -amides used as 5-HT4 receptor antagonists
GB9219163D0 (en) * 1992-09-10 1992-10-28 Smithkline Beecham Plc Pharmaceuticals
MX9306311A (es) 1992-10-13 1994-04-29 Smithkline Beecham Plc Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
EP0667867A1 (en) * 1992-11-05 1995-08-23 Smithkline Beecham Plc Piperidine derivatives as 5-ht4 receptor antagonists
GB9301660D0 (en) * 1993-01-28 1993-03-17 Smithkline Beecham Plc Pharmaceuticals
GB9312348D0 (en) * 1993-06-16 1993-07-28 Smithkline Beecham Plc Pharmaceuticals
IT1275903B1 (it) * 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
GB9507882D0 (en) * 1995-04-18 1995-05-31 Pharmacia Spa Substituted dihydrobenzofuran derivatives as 5-ht4 agonists
TW445263B (en) * 1996-02-29 2001-07-11 Janssen Pharmaceutica Nv Novel esters of 1,4-disubstituted piperidine derivatives

Also Published As

Publication number Publication date
AU1767897A (en) 1997-09-16
US6509339B2 (en) 2003-01-21
JP2000505461A (ja) 2000-05-09
US6291481B1 (en) 2001-09-18
DE69721742T2 (de) 2004-03-11
MY121632A (en) 2006-02-28
AU724401B2 (en) 2000-09-21
US20030153573A1 (en) 2003-08-14
ID17758A (id) 1998-01-22
ATE239706T1 (de) 2003-05-15
ES2199341T3 (es) 2004-02-16
DE69721742D1 (de) 2003-06-12
US6800628B2 (en) 2004-10-05
EP0885190B1 (en) 2003-05-07
TW445263B (en) 2001-07-11
KR19990082000A (ko) 1999-11-15
WO1997031897A1 (en) 1997-09-04
ZA971735B (en) 1998-08-27
EP0885190A1 (en) 1998-12-23
US20020042430A1 (en) 2002-04-11
KR100485148B1 (ko) 2006-05-03

Similar Documents

Publication Publication Date Title
AR006518A1 (es) Esteres de derivados de 1,4-piperidina disustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y un procedimiento para su preparacion
AR013361A1 (es) BENZAMIDAS BICíCLICAS DE DERIVADOS 3-o4-SUBSTITUíDOS DE 4-(AMINOMETIL)- PIPERIDINAS, PROCEDIMIENTO PARA SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE, PROCEDIMIENTO PARA SU PREPARACIoN, COMPUESTO INTERMEDIARIO Y PROCEDIMIENTO PARA SU PREPARACIoN.
MY121852A (en) 4-(aminoethyl)-piperidine benzamides for treating gastrointestinal disorders
LTIP846A (en) N-(4-piperidinyl)(dihydrobenzofuran or dihydro-2h-benzopyran)carboxamide derivatives,processes for the preparation thereof and pharmaceutical compositions
RU2008112290A (ru) Производные пиридазинона, используемые для лечения боли
ES2155535T3 (es) Inhibidores de sintesis de apoliproteina b.
AR033942A1 (es) Compuestos de monofluoroalquilo aplicables en la potenciacion de los compuestos intermediarios utilizables en la sintesis de dichos compuestos de monofluoralquilo; composiciones farmaceuticas formuladas con dichos compuestos potenciadores y metodos para la potenciacion de las funciones de dichos rec
AR002025A1 (es) Derivados de 4-(1h-indol-1-il)-1-piperidinilo, su uso y un procedimiento para su preparacion, una composicion farmaceutica que los contiene, unprocedimiento para la preparacion de dicha composicion farmaceutica.
AR035311A1 (es) Derivados de acido hidroxamico que contienen alquinilo, como inhibidores de las metalloproteinasas de matriz y de la tace, composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento
AR009987A1 (es) Derivados de beta-tiopropionilaminoacidos, composiciones farmaceuticas que incluyen dichos derivados, procedimiento para prepararlos, uso de dichosderivados para el tratamiento de infecciones bacterianas y compuestos intermediarios de aplicacion en dicho procedimiento
CA2242494A1 (en) Novel n-substituted 4-((4'-aminobenzoyl)-oxymethyl)-piperidines having gastric prokinetic properties
OA09114A (fr) Nouveaux dérivés hétéroarotinoïdes, leurs procédés de préparation et les compositions pharceutiques qui les contiennent.
AR005834A1 (es) Esteres de derivados de 3-hidroxipiperidinmetanol, un procedimiento para su preparacion, una composicion farmaceutica que los contiene, un procedimiento para preparar dicha composicion, un compuesto intermediario y un proceso para preparar un compuesto intermediario.
CO4750648A1 (es) 5-naftalen-1-il-1,3 dioxanos, su preparacion y composiciones farmaceuticas que los contienen
NZ509327A (en) Alpha-amino acid phenyl ester derivatives for use in general anaesthesia
CA2235133A1 (en) Esters of 3-hydroxy-piperidinemethanol derivatives
TH54463A3 (th) 4-(อะมิโนเมธิล)-พิเพอริดีน เบนแซมีด สำหรับรักษาโรคเกี่ยวกับกระเพาะอาหารและลำไส้
ES8703453A1 (es) Un procedimiento para preparar derivados de bencimidazol
ECSP993066A (es) Derivados de fenil esteres de alfa- aminoacidos y su uso como hipnoticos para la induccion y mantencion de la anestesia general
CO4230089A1 (es) Derivados inotropicos y lusitropicos positivos de pirrolo- quinona, composicones farmaceuticas que los contienen y pro- cedimiento para su fabricacion
ECSP003774A (es) Derivados de espiro 2h-1-benzopiran-2,4¿-piperidina

Legal Events

Date Code Title Description
FG Grant, registration